Financhill
Buy
65

VCYT Quote, Financials, Valuation and Earnings

Last price:
$24.22
Seasonality move :
-0.16%
Day range:
$24.86 - $25.62
52-week range:
$19.73 - $47.32
Dividend yield:
0%
P/E ratio:
61.39x
P/S ratio:
4.30x
P/B ratio:
1.65x
Volume:
833.6K
Avg. volume:
950K
1-year change:
-1.53%
Market cap:
$2B
Revenue:
$445.8M
EPS (TTM):
$0.41

Analysts' Opinion

  • Consensus Rating
    Veracyte has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $40.33, Veracyte has an estimated upside of 60.24% from its current price of $25.17.
  • Price Target Downside
    According to analysts, the lowest downside price target is $29.00 representing 100% downside risk from its current price of $25.17.

Fair Value

  • According to the consensus of 9 analysts, Veracyte has 60.24% upside to fair value with a price target of $40.33 per share.

VCYT vs. S&P 500

  • Over the past 5 trading days, Veracyte has underperformed the S&P 500 by -7.11% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Veracyte does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Veracyte has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Veracyte reported revenues of $114.5M.

Earnings Growth

  • Veracyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Veracyte reported earnings per share of $0.09.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
4.30x
EV / EBIT:
58.43x
EV / Revenue:
3.63x
PEG ratio (5yr expected):
-0.48x
EV / Free cash flow:
21.46x
Price / Operating cash flow:
25.37x
Enterprise value / EBITDA:
32.35x
Gross Profit (TTM):
$315.2M
Return On Assets:
2.61%
Net Income Margin (TTM):
7.13%
Return On Equity:
2.85%
Return On Invested Capital:
2.85%
Operating Margin:
1.02%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $311.2M $375.5M $463.4M $96.8M $114.5M
Gross Profit $187.8M $240.8M $315.2M $62.5M $79.5M
Operating Income -$32.4M -$12.4M $24.8M -$3.7M $1.2M
EBITDA -$3.9M -$46.1M $52M $1.9M $6.5M
Diluted EPS -$0.41 -$0.94 $0.41 -$0.02 $0.09
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $362.1M $238.5M $251.5M $290.4M $383.2M
Total Assets $1B $1.2B $1.2B $1.2B $1.3B
Current Liabilities $32.7M $62.5M $56M $58.1M $75.1M
Total Liabilities $50.9M $88.4M $75.9M $81.4M $120.5M
Total Equity $974.2M $1.1B $1.1B $1.1B $1.2B
Total Debt $863K $1.1M -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $14.2M $37.4M $89.4M -$9M $5.4M
Cash From Investing -$2.9M -$6.1M -$111M $2.9M -$51.8M
Cash From Financing $3.2M $288K -$716K -$864K -$6.5M
Free Cash Flow $7.1M $26.3M $78.5M -$11.1M $3.5M
VCYT
Sector
Market Cap
$2B
$34.4M
Price % of 52-Week High
53.2%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-1.53%
-37.36%
Beta (5-Year)
2.071
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $26.46
200-day SMA
Sell
Level $34.49
Bollinger Bands (100)
Sell
Level 26.78 - 32.94
Chaikin Money Flow
Sell
Level -912.7K
20-day SMA
Sell
Level $26.77
Relative Strength Index (RSI14)
Sell
Level 35.24
ADX Line
Sell
Level 25.24
Williams %R
Buy
Level -89.9676
50-day SMA
Sell
Level $27.64
MACD (12, 26)
Buy
Level 7.11
25-day Aroon Oscillator
Sell
Level -92
On Balance Volume
Sell
Level -751.9K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (15.0951)
Buy
CA Score (Annual)
Level (1.7006)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-5.0901)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Stock Forecast FAQ

In the current month, VCYT has received 7 Buy ratings 1 Hold ratings, and 1 Sell ratings. The VCYT average analyst price target in the past 3 months is $40.33.

  • Where Will Veracyte Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Veracyte share price will rise to $40.33 per share over the next 12 months.

  • What Do Analysts Say About Veracyte?

    Analysts are divided on their view about Veracyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Veracyte is a Sell and believe this share price will drop from its current level to $29.00.

  • What Is Veracyte's Price Target?

    The price target for Veracyte over the next 1-year time period is forecast to be $40.33 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is VCYT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Veracyte is a Buy. 7 of 9 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of VCYT?

    You can purchase shares of Veracyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Veracyte shares.

  • What Is The Veracyte Share Price Today?

    Veracyte was last trading at $24.22 per share. This represents the most recent stock quote for Veracyte. Yesterday, Veracyte closed at $25.17 per share.

  • How To Buy Veracyte Stock Online?

    In order to purchase Veracyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock